Lecture Details - Overview
Continuing Education Information
Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
E-Lert: Updates on Therapeutic Options for Breast Cancer - Targeted Agents
Release Date: December 3, 2009|
Expiration Date: December 3, 2010
0.5 AMA PRA Category 1 Credit(s)™|
Dec 3, 2009, E-Lert
Lecture Overview
Recent data on the treatment of breast cancer reflect a focus on targeted therapies. The novel approach of inhibiting poly(ADP-ribose) polymerase (PARP) in tumors with defective BRCA1/2 signaling might be particularly effective in triple-negative disease, for which no targeted approach is available. Studies are also examining the optimal chemotherapeutic partners for antiangiogenic therapy in metastatic breast cancer (MBC). In HER2+ disease, the role of focal HER2-amplified clones in the interpretation of HER2 testing and benefit from therapy is under investigation. Lastly, HER2-targeted antibody-drug conjugates and novel small-molecule tyrosine kinase inhibitors are demonstrating activity in patients with disease progression on standard HER2-targeted therapy, potentially increasing therapeutic options beyond progression.
The purpose of this activity is to update physicians on the latest clinically relevant data on targeted therapies in the treatment of breast cancer.
This educational activity is intended for medical oncologists involved in the care of patients with breast cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.Upon completion of this educational activity, you should be able to:
- Assess recent data regarding the safety and efficacy of inhibitors of PARP in patients with advanced breast cancer
- Evaluate recent data concerning the efficacy of antiangiogenic therapy combined with various cytotoxic agents for the treatment of MBC
- Discuss recent advances regarding the efficacy and safety of HER2-targeted therapy beyond progression on standard therapies for HER2+ advanced breast cancer
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- View the Flash video presentations and slides.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
You will be permitted 2 attempts to successfully complete the Posttest.
Complete the test(s) and evaluation by December 3, 2010 to receive your certificate online.
Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:
Disclosure Policy
It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.
Howard A. Burris III, MD, FACP
No relevant relationships to disclose.
PER Editorial Staff
No relevant relationships to disclose
This CME activity includes discussion of investigational and/or unlabeled uses of drugs, including the use of BSI-201; gemcitabine/carboplatin; olaparib; bevacizumab in combination with docetaxel, albumin-bound paclitaxel, capecitabine, or ixabepilone; sorafenib/capecitabine; trastuzumab-DM1; neratinib (HKI-272) monotherapy or in combination with trastuzumab; and BIBW 2992 in advanced/metastatic breast cancer. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
Commercial Support
An educational grant for this activity was provided by Genentech BioOncology.
Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.
If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.
PC Users
If you need to upgrade your Web browser, follow one of the links listed below:
- Microsoft Internet Explorer (Outside Source)
- Mozilla Firefox (Outside Source)
Additional software requirements include:
- Adobe Flash Player (Outside Source)
- Apple iTunes for Podcast (Outside Source)
- Adobe Acrobat Reader (Outside Source)
Macintosh Users
Compatible Web browsers include:
- Mozilla Firefox (Outside Source)
- Apple Safari (Outside Source)
Additional software requirements include:
- Adobe Flash Player (Outside Source)
- Apple iTunes for Podcast (Outside Source)
- Adobe Acrobat Reader (Outside Source)
Disclaimer
The views and opinions expressed in this learning activity are those of the presenter and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenter and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.
Please consult full prescribing information for any drugs or procedures discussed within.
Privacy Policy
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.
All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.
All correspondence should be directed to:
Editor, Updates on Therapeutic Options for Breast Cancer: Targeted Agents
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology